Clinical Report: Effects of Chemotherapy on Lymphedema in Breast Cancer Patients
Overview
This study investigates the association between chemotherapy and breast cancer-related lymphedema (BCRL) in 201 patients. Significant findings indicate that taxane-based regimens, long-course chemotherapy, and combined neoadjuvant and adjuvant chemotherapy increase the risk of BCRL.
Background
Breast cancer-related lymphedema (BCRL) is a common complication that can severely affect patients' quality of life. Identifying risk factors associated with BCRL is crucial for developing targeted prevention strategies. This study addresses the controversial role of chemotherapy in BCRL risk, providing insights for clinical management.
Data Highlights
Characteristic
Odds Ratio (OR)
95% Confidence Interval (CI)
Taxane-based regimens
4.018
1.162–13.890
Long-course chemotherapy
4.887
1.396–17.116
Combined neoadjuvant and adjuvant chemotherapy
4.50
1.14–17.762
Key Findings
BCRL occurred in 15.4% of the studied patients.
Univariate analysis showed significant associations between BCRL and chemotherapy, axillary lymph node dissection, and tumor stage.
Taxane-based chemotherapy regimens were linked to a higher risk of BCRL.
Long-course chemotherapy significantly increased the odds of developing BCRL.
The combination of neoadjuvant and adjuvant chemotherapy was associated with a notable increase in BCRL risk.
Clinical Implications
Healthcare providers should be aware of the increased risk of BCRL associated with specific chemotherapy regimens. Vigilant monitoring for signs of lymphedema in patients receiving taxane-based or long-course chemotherapy is essential for early intervention and improved patient outcomes.
Conclusion
The findings underscore the need for careful consideration of chemotherapy regimens in breast cancer treatment planning to mitigate the risk of lymphedema. Enhanced monitoring strategies may improve long-term management for breast cancer survivors.
